William F. Kabourek, the crusty credit analyst (http://thecrustycreditanalyst.blogspot.com/), is a retired 65 year old. His business experience includes being president of two commercial banks, owner of 25 furniture rental stores, and partner in a private equity firm. William is retired for 15 years and still solvent.
I am a fundamentally oriented value investor who complements this with technical analysis to help optimize price points selected for buying and selling.
I like companies with
* significant price to free cash flow
* high return on invested capital and return on equity
* book-adjusted earnings or cash returns exceeding 10%
In terms of geographical focus, I am willing to invest in most markets worldwide. I am skeptical of most Chinese companies trading outside of Hong Kong.
I am a value investor but with an emphasis on two things: Technicals and Dividends. This emphasis lets me play it safe and minimize my risk.
Assuming a value stock is actually a good deal and not just a value trap, with many there eventually should come a chart pattern that shows that others are beginning to realize what you realize: That this stock is undervalued. This also lets you time your investments for maximum returns.
Dividends, meaning safe and dependable dividends and not "sucker yields", also are a strong subplay on value. "Getting paid to wait" for a turnaround is not only an efficient return on your money while waiting for the turnaround, it also brings substantial piece of mind.
Last year (2010), I called chart breakouts on value plays XOM (Symmetrical Triangle), Alcoa (Double Bottom), Lowe's (Ascending Triangle), Goldman Sachs (Ascending Triangle) and most recently JPM Chase (ascending triangle), as well as noting the S&P Rising Three Methods in late September that portended a beautiful upswing.
I am an honors graduate from University of Florida and I've been an investor for 4 years now and loved every minute of it. The Great Recession was not the easiest time to learn the ropes, but "A calm sea never made a great sailor". I look forward to getting any and all feedback, and wish all of you the best of luck in your investing.
Dr. Suleman (Suli) Verjee, Ph.D., President and CEO of Versante International, LLC., has over 30 years of drug development experience with both pharmaceutical and biotechnology companies. Prior to founding Versante, a full service biometrics-focused contract research organization in 2002, Dr. Verjee held senior management positions at several leading multinational companies. These include Abbott Laboratories, Ethicon Inc. (a division of Johnson and Johnson), Parke-Davis/Warner Lambert, Bristol-Myers Company, Lorex Pharmaceuticals, Berlex Laboratories (now part of Bayer) and Dendreon Corporation.
Dr. Verjee has an intimate knowledge of all phases of drug development and has a track record of successful New Drug (NDA) and Biological License (BLA) Applications. The drug development programs he has been associated with and made significant contributions to include those for Ambien, Betaseron, Buspar, Depakene, Enkaid, Fludara, Kerlone and Provenge. His numerous interactions with regulatory agencies include Special Protocol Assessments (SPA), Electronic Submissions and Advisory Committee Meetings. He has been a member of several data safety monitoring and scientific advisory boards. Dr. Verjee’s experience spans hundreds of clinical studies.
Dr. Verjee received his doctoral degree in Statistics from the University of Chicago where he studied under Professors Shelby Haberman and Paul Meier. His academic teaching experience includes teaching undergraduate statistics courses at the University of Chicago and the University of Illinois as well as graduate level courses in statistics at IMPA (Instituto de Matematica, Pura e Aplicada in Rio de Janeiro), Universidade de Campinas (San Paulo) and the Universidade Federal de Minas Gerais (Belo Horizonte).
Equity & Commodity Derivatives Trader in Chicago, IL
3.5 Years w/ Belvedere Trading, Chicago, IL
3.0 Years w/ UBS Program Trading Desk, Stamford, CT
33 years old, MS Engineering Stanford University
Active Personal Account Trader in Options/Futures
Love running, skiing, scuba, traveling, soccer, wine, life.